18 citations
,
August 2019 in “Clinical breast cancer” This meta-analysis found that in postmenopausal women with a history of breast cancer, 8 weeks of vaginal estrogen therapy while on aromatase inhibitors did not result in systemic absorption of sex hormones, suggesting potential safety for treating vulvovaginal atrophy in this context.
December 2025 in “Pakistan Journal of Health Sciences” This systematic review found that estrogen deficiency in postmenopausal women leads to structural and symptomatic changes in genital and cutaneous tissues, with local estrogen therapy providing short-term benefits, while evidence for device-based treatments remains limited and requires larger trials.
30 citations
,
December 2001 in “Journal of The European Academy of Dermatology and Venereology” This paper discusses hormonal therapy options for women with severe acne, focusing on treatment for cases that do not respond to conventional methods, but it reports no new clinical findings.
January 2011 in “Padua Research Archive (University of Padua)” This study suggests that human skin locally synthesizes active sex steroid hormones, impacting inflammation, cell behavior, and wound healing, with potential implications for therapies in aging and impaired wound recovery.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.